Richard E Champlin Selected Research

Cytarabine (Cytosar-U)

1/2019	Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
1/2018	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
1/2017	A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
2/2016	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
4/2005	Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard E Champlin Research Topics

Disease

75	Neoplasms (Cancer) 01/2022 - 01/2002
59	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 01/2002
51	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 03/2002
33	Multiple Myeloma 05/2022 - 04/2004
31	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2002
28	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 08/2004
26	Lymphoma (Lymphomas) 01/2022 - 04/2003
24	Infections 01/2021 - 11/2002
20	Leukemia 01/2022 - 11/2004
15	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 03/2002
15	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2016 - 01/2002
11	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2017 - 02/2004
9	Disease Progression 01/2021 - 03/2003
9	Breast Neoplasms (Breast Cancer) 01/2013 - 05/2003
8	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 06/2006
8	Residual Neoplasm 01/2020 - 08/2014
8	Bronchiolitis Obliterans Syndrome 01/2016 - 02/2005
7	Myeloid Leukemia (Leukemia, Myelocytic) 11/2018 - 11/2008
6	Philadelphia Chromosome 01/2021 - 08/2013
6	Primary Myelofibrosis (Myelosclerosis) 01/2021 - 04/2010
6	Neutropenia 03/2016 - 02/2005
5	Hemorrhagic Cystitis 01/2021 - 08/2009
5	Mycoses (Diseases, Fungus) 12/2020 - 02/2005
5	Chromosome Aberrations (Chromosome Abnormalities) 01/2018 - 09/2007
4	B-Cell Lymphoma (Lymphoma, B Cell) 12/2022 - 01/2021
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 09/2008
4	Pathologic Complete Response 11/2020 - 11/2014
4	Respiratory Tract Infections (Respiratory Tract Infection) 08/2014 - 11/2012
4	Respiratory Syncytial Virus Infections 08/2014 - 09/2010
4	Aplastic Anemia (Anemia, Hypoplastic) 02/2014 - 05/2007
3	COVID-19 12/2021 - 01/2021
3	Frailty 03/2020 - 04/2007
3	Immunoglobulin Light-chain Amyloidosis 11/2018 - 08/2015
3	Renal Insufficiency (Renal Failure) 01/2018 - 07/2009
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 04/2009 - 12/2003
3	Invasive Fungal Infections 12/2007 - 02/2005

Drug/Important Bio-Agent (IBA)

35	Busulfan (Busulfex)FDA Link 01/2022 - 01/2002
33	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 10/2002
32	fludarabineIBA 01/2022 - 10/2002
25	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 01/2002
17	Tacrolimus (Prograf)FDA LinkGeneric 12/2021 - 11/2003
17	AntigensIBA 01/2021 - 03/2002
12	Chimeric Antigen ReceptorsIBA 01/2022 - 10/2010
12	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 11/2003
11	Rituximab (Mabthera)FDA Link 01/2021 - 01/2004
10	Clofarabine (Clolar)FDA Link 01/2022 - 06/2011
8	DNA (Deoxyribonucleic Acid)IBA 11/2018 - 05/2012
8	Antiviral Agents (Antivirals)IBA 01/2018 - 09/2006
8	Gemcitabine FDA Link 11/2017 - 03/2012
7	NucleosidesIBA 10/2016 - 05/2012
6	Bortezomib (Velcade)FDA Link 01/2022 - 05/2012
6	CytokinesIBA 01/2021 - 11/2002
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 11/2004
6	Alkylating AgentsIBA 11/2018 - 05/2012
5	Lenalidomide (CC 5013)FDA Link 01/2022 - 03/2013
5	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 03/2007
5	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2019 - 04/2005
5	Imatinib Mesylate (Gleevec)FDA Link 08/2013 - 03/2003
4	SteroidsIBA 01/2022 - 11/2002
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 02/2016
4	Mycophenolic Acid (Cellcept)FDA LinkGeneric 12/2021 - 03/2016
4	Tyrosine Kinase InhibitorsIBA 01/2021 - 06/2011
4	Calcineurin InhibitorsIBA 10/2019 - 01/2015
4	Carmustine (FIVB)FDA Link 01/2019 - 11/2004
4	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2018 - 05/2007
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2016 - 02/2006
4	HLA Antigens (Human Leukocyte Antigens)IBA 12/2014 - 03/2002
3	Vorinostat FDA Link 01/2022 - 05/2012
3	HLA-DPB1 antigen (HLA DPB1)IBA 01/2022 - 01/2018
3	RNA (Ribonucleic Acid)IBA 01/2021 - 09/2012
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 06/2006
3	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 04/2005
3	Decitabine FDA Link 11/2018 - 03/2010
3	Proteasome InhibitorsIBA 11/2018 - 03/2016
3	Immunomodulating AgentsIBA 11/2018 - 03/2016
3	fms-Like Tyrosine Kinase 3IBA 04/2017 - 11/2014
3	Pharmaceutical PreparationsIBA 09/2016 - 06/2009
3	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 03/2016 - 11/2004
3	InterferonsIBA 01/2015 - 02/2005
3	Ribavirin (Virazole)FDA LinkGeneric 05/2014 - 11/2012
3	Biological ProductsIBA 02/2013 - 07/2002
3	Monoclonal AntibodiesIBA 06/2012 - 11/2009
3	HLA-A Antigens (HLA-A)IBA 12/2011 - 03/2002
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2010 - 12/2003
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2009 - 12/2003

Therapy/Procedure

81	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2002
70	Stem Cell Transplantation 12/2022 - 01/2002
66	Transplantation 01/2022 - 01/2002
62	Therapeutics 01/2022 - 07/2002
31	Drug Therapy (Chemotherapy) 01/2022 - 05/2003
18	Cell Transplantation 05/2022 - 10/2008
14	Homologous Transplantation 01/2019 - 10/2002
8	Autologous Transplantation 01/2021 - 06/2004
8	Immunotherapy 01/2021 - 05/2010
8	Bone Marrow Transplantation (Transplantation, Bone Marrow) 11/2014 - 03/2002
7	Haploidentical Transplantation 12/2019 - 03/2012
5	Investigational Therapies (Experimental Therapy) 11/2016 - 04/2006
3	Salvage Therapy 01/2018 - 06/2004
3	Blood Component Removal (Apheresis) 01/2017 - 07/2011
3	Induction Chemotherapy 12/2016 - 09/2008